Bimatoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the evidence pack as given. One note up front: I did not follow predicted_indications[0] mechanically. Rank 1 ("malformation syndrome with odontal/periodontal component") has 0 clinical trials and 20 completely unrelated periodontitis papers that never mention bimatoprost — the evidence pack's own rationale field calls this "literature noise, not evidence." Ranks 2–7 and 10 are similarly unsupported (several are even mechanistically backwards, e.g. predicting a hair-growth drug for a hypertrichosis syndrome). The only candidate in this pack with real trial and literature support is rank 8, alopecia (L2, "Proceed with Guardrails"), so the report is built around that.
Bimatoprost: From Glaucoma to Alopecia
One-Sentence Summary
Bimatoprost is a synthetic prostamide F2α analog originally approved (per literature evidence in this pack) for glaucoma/ocular hypertension and, as an ophthalmic solution, for eyelash hypotrichosis (Latisse™). The TxGNN model predicts it may also be effective for Alopecia (androgenetic alopecia, alopecia areata, and related hair-loss conditions), with 11 clinical trials and 20 publications currently supporting this direction.
Note: TxGNN's single highest-scoring prediction in this evidence pack (a periodontal malformation syndrome) and several others (Dandy-Walker syndrome, hair-shaft abnormality, hypertrichosis, pulmonary AV malformation) have no supporting evidence and in some cases are mechanistically implausible or backwards — they are excluded from this report and flagged "Hold" in the source data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Glaucoma / ocular hypertension (ophthalmic); eyelash hypotrichosis (per literature evidence — not confirmed via Finland regulatory data, as the product is not marketed there) |
| Predicted New Indication | Alopecia (androgenetic alopecia / alopecia areata) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank MOA data is not available for bimatoprost in this evidence pack (flagged as a High-severity data gap). However, the clinical trial and literature evidence themselves describe bimatoprost as a synthetic prostamide F2α analog. In ophthalmology it lowers intraocular pressure by increasing aqueous humor outflow; as a well-documented side effect, it also prolongs the hair follicle anagen (growth) phase, which is the basis for its FDA-approved use (Latisse™) in treating eyelash hypotrichosis.
This anagen-prolongation mechanism is not specific to eyelashes — hair follicle biology is broadly shared across eyelash, eyebrow, and scalp follicles. Multiple sponsor-run trials (Allergan) directly tested this hypothesis by applying bimatoprost topically to the scalp in androgenetic alopecia (AGA) and female pattern hair loss, and to eyebrows/eyelashes after chemotherapy-induced loss. A related, weaker-evidence entry in the same pack ("genetic alopecia," L4, case-report level) supports the same mechanistic direction.
In short, the prediction is reasonable because it is not a novel hypothesis inferred purely from the TxGNN graph — it is a mechanism that has already been prospectively tested in multiple completed Phase 1/2 trials, including two placebo/active-comparator RCTs with >300 participants each (against minoxidil).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01325350 | Phase 2 | Completed | 306 | RCT of 3 bimatoprost doses vs. vehicle and OTC minoxidil 2% in women with female pattern hair loss |
| NCT01325337 | Phase 2 | Completed | 307 | RCT of 3 bimatoprost doses vs. vehicle and OTC minoxidil 5% in men with androgenic alopecia |
| NCT01904721 | Phase 2 | Completed | 244 | Safety and efficacy of bimatoprost in men with androgenic alopecia (AGA) |
| NCT02170662 | Phase 2 | Completed | 33 | Effect of bimatoprost 0.03% ophthalmic solution on androgen-dependent scalp hair follicles |
| NCT01189279 | Phase 1 | Completed | 42 | Safety, tolerability and pharmacokinetics of new topical bimatoprost formulations in alopecia patients |
| NCT02848300 | Phase 1 | Completed | 11 | Scalp pharmacokinetics and tolerability of two bimatoprost formulations after 14 days topical application in AGA |
| NCT01023841 | Phase 4 | Completed | 71 | Safety/efficacy of bimatoprost 0.03% for eyelash loss or hypotrichosis in children |
| NCT05600673 | Phase 1/2 | Completed | 30 | Combined CO2 fractional laser + bimatoprost 0.03% in alopecia areata |
| NCT00187577 | N/A | Completed | 14 | Latanoprost vs. bimatoprost ophthalmic solutions for eyelash regrowth in alopecia areata |
| NCT02676310 | Phase 1 | Terminated | 53 | Dose-escalation safety/tolerability/PK study of topical bimatoprost in men with AGA (terminated, incomplete) |
(One additional trial, NCT00999557, was withdrawn with 0 enrollment and is omitted as uninformative.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32250713 | 2022 | Systematic Review / Network Meta-analysis | J Dermatolog Treat | Compares relative efficacy of non-surgical AGA monotherapies in men and women |
| 29863806 | 2018 | Guideline | J Dermatol | Japanese clinical guideline for diagnosis and treatment of male/female pattern hair loss |
| 28264599 | 2017 | Review | Expert Opin Investig Drugs | Reviews bimatoprost for eyelash, eyebrow and scalp alopecia; notes FDA approval for eyelash hypotrichosis |
| 40252129 | 2025 | Clinical Study | Arch Dermatol Res | CO2 fractional laser + bimatoprost combination enhances hair regrowth in alopecia areata |
| 35278027 | 2022 | Prospective Open-Label Study | Dermatol Ther | Topical bimatoprost for eyelash loss in alopecia totalis/universalis; 16/1x responders |
| 37089845 | 2023 | Non-randomized Open-Label Clinical Trial | Indian Dermatol Online J | Bimatoprost vs. clobetasol propionate in scalp alopecia areata |
| 37185388 | 2023 | Review | Curr Oncol | Reviews chemotherapy-induced alopecia treatments including prostaglandin analogs |
| 32642317 | 2020 | Review | Dermatol Pract Concept | Prevention and treatment options for chemotherapy-induced alopecia |
| 35040730 | 2022 | Preclinical/Formulation | Drug Deliv | Enhanced-penetration topical bimatoprost formulation shows in vivo hair regrowth efficacy in androgenic alopecia |
| 38577618 | 2024 | Preclinical/Formulation | Int J Pharm X | Nanogel delivery system improves cutaneous bimatoprost deposition and hair regrowth in androgenic alopecia |
Finland Market Information
Bimatoprost is not currently marketed in Finland — no marketing authorizations are recorded (0 licenses).
Safety Considerations
Please refer to the package insert for safety information (no structured warnings, contraindications, or DDI data are available in this evidence pack; the TFDA/Fimea package insert lookup is flagged as a Blocking data gap). For context, the literature evidence in this pack (e.g. PMID 29854658) notes that prostaglandin-analog eye drops of this class are associated with eyelid pigmentation and localized hypertrichosis as known class effects — this is cited from the literature evidence, not from a validated safety data source, and should not substitute for the formal package insert.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Three completed Phase 2 RCTs (two with >300 participants, one against active minoxidil comparators) directly support bimatoprost's efficacy on scalp/eyebrow hair growth, consistent with its already-validated anagen-prolongation mechanism (FDA-approved for eyelash hypotrichosis). However, no completed Phase 3 trial exists, one AGA dose-escalation trial was terminated early, and the product is not currently marketed in Finland, so safety and regulatory data are incomplete.
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently a Blocking data gap
- Confirmed DrugBank mechanism-of-action documentation
- A completed Phase 3 confirmatory trial in the target alopecia population before any indication filing
- Drug-drug interaction data (current query status: not found)
- A defined regulatory pathway/strategy for Finland market entry given current "not marketed" status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.